-
Mashup Score: 0
A research team developed a study to implement aPROMISE for the evaluation of both PSMA and FDG-PET/CT scans that are acquired prior to PSMA RLT.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0
Dr. Albiges details what KEYMAKER-U03B hopes to accomplish, outcomes for patients in arm B5, and next lines of research for belzutifan.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
We spoke with Laurence Albiges, MD, PhD (@AlbigesL), about previous research on #belzutifan in pretreated #RCC prior to the KEYMAKER-U03B trial, and what the next line of research may be for belzutifan for patients with progressive RCC. Watch now: https://t.co/hVGtmV5ogE https://t.co/FB4Z6DGUSA
-
-
Mashup Score: 0
The VISION trial assigned patients with mCRPC to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
A new analysis of the VISION trial, led by Karim Fizazi, MD, PhD, revealed additional outcomes related to health-related quality of life, pain, and symptomatic skeletal events. Learn more: https://t.co/NT8VkN6K33 https://t.co/zhDfjQCk12
-
-
Mashup Score: 2Panelists Discuss Treatment Approach for Patients With Cisplatin-Eligible Bladder Cancer | GU Oncology Now - 2 year(s) ago
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
A roundtable discussion led by @koshkin85 featured panelists @mattzibelman, @cnsternberg, and @DanielPetrylak discussing the approach to treating patients with cisplatin-eligible bladder cancer. Watch now: https://t.co/0gtxaCC16I https://t.co/x6KK7yqhTl
-
-
Mashup Score: 0
Researchers utilized nnU-Net, a deep learning-based segmentation method, to segment and localize sites that may be suspicious for prostate cancer.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
Researchers have found that a neural network-based method in conjunction with 68Ga-PSMA-11 and 18F-DCFPyL PET/CT could segment and localize sites that may be suspicious for #prostatecancer for nodal and metastatic staging. Read more: https://t.co/dDhc2mna5B #SNMMI23 https://t.co/peF0V2FJau
-
-
Mashup Score: 0
As TTV is a lengthy process, researchers examined the efficacy of utilizing an algorithm developed by deep learning to automatically generate TTV on Lu-SPECT.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
The utilization of TTV and whole-body SUVmean on 177Lu-PSMA SPECT/CT can predict outcomes in patients with mCRPC who are receiving 177Lu-PSMA therapy. Learn how an algorithm developed by deep learning could automatically generate TTV on Lu-SPECT: https://t.co/E7RiR6tfvw https://t.co/NIAH4zBS0z
-
-
Mashup Score: 0
Drs. Grivas and Wallis discuss the nuances of approaching perioperative systemic therapy in patients with upper and lower tract disease.
Source: GU Oncology NowCategories: Latest HeadlinesTweet-
Very lucky to speak with @PGrivasMDPhD recently about systemic therapy in UTUC including peri-operative and metastatic settings. Check out his insights on @GUOncologyNow : Peri-op: https://t.co/Rr2vjnBwhr Targeted therapies in metastatic disease: https://t.co/YDiXwZB5Dv
-
-
Mashup Score: 0
A study assessed and compared bone marrow dosimetry using blood-, image-, and whole-body skeleton-based methods for patients treated with 177Lu-PSMA-617.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
A group of researchers sampled patients treated with 177Lu-PSMA-617 to determine the efficacy of bone marrow dosimetry using blood-based, image-based, and whole-body skeleton-based methods. Learn more: https://t.co/ZbFHHYD0FD #SNMMI23 https://t.co/ptTrNJII0A
-
-
Mashup Score: 0
Researchers studied the clinical use of PSMA PET, its impact on the management of biochemical recurrence, and its relationship to other clinical parameters.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
How have the clinical management plans of patients with prostate cancer changed since the @us_fda approval of PSMA PET in 2021? A study from #SNMMI23 reveals the treatment's impact: https://t.co/qLvlmNyKWZ https://t.co/Vqm6es4jwW
-
-
Mashup Score: 0
A study compared the outcomes of patients who received enzalutamide as an AR signaling inhibitor with patients who did not receive enzalutamide prior to Lu-PSMA.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
At #SNMMI23, new data was presented comparing the outcomes of patients with #prostatecancer who received enzalutamide as an androgen receptor signaling inhibitor with patients who did not receive enzalutamide prior to Lu-PSMA. Learn more about this study: https://t.co/2mgNSCf6gH https://t.co/MB1qET2KS0
-
Could an #AI-based platform help evaluate PSMA and FDG-PET/CT scans for patients with #mCRPC? Learn about the recent study of the aPROMISE platform, which utilizes deep learning to extract anatomical data from CT images: https://t.co/jMjfhviwpr https://t.co/CRRkuTJBFp